(Albany, New York) – October 20, 2026: DelveInsight’s “Esophageal Cancer Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Esophageal Cancer, historical and forecasted epidemiology as well as the Esophageal Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Esophageal Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Esophageal Cancer Market Forecast
Some of the key facts of the Esophageal Cancer Market Report:
In 2025, the esophageal cancer market size was valued at approximately USD 1,300 million, and it is projected to grow at a compound annual growth rate (CAGR) 6.0% from 2025 to 2036, indicating steady expansion driven by evolving treatment approaches and increasing therapeutic advancements.
In OCtober 2026, A Phase II randomized study published in Clinical Cancer Research on October 1, 2026, evaluated lomvastomig (PD-1/TIM-3 bispecific antibody) and tobemstomig (PD-1/LAG-3 bispecific antibody) against nivolumab in previously treated, advanced or metastatic ESCC.
In August 2026, the FDA approved zanidatamab-hrii (Ziihera) with fluoropyrimidine- and platinum-based chemotherapy, plus tislelizumab-jsgr (Tevimbra), for first-line treatment of adults with HER2-positive, unresectable locally advanced or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma.
In August 2026, Leads Biolabs announced that its Phase II study of opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody, had completed the safety run-in and advanced to the expansion stage.
In June 2026, At the 2026 ASCO Annual Meeting, investigators presented Phase II findings from SCALE-2, which evaluated short-course radiotherapy followed by chemotherapy and toripalimab before surgery in resectable, locally advanced ESCC.
In November 2025, Pembrolizumab (KEYTRUDA) in combination with chemotherapy showed sustained long-term survival benefit in advanced esophageal cancer, with 5-year follow-up data from the Phase III KEYNOTE-590 study confirming improved overall survival and progression-free survival versus chemotherapy alone.
In June 2025, The FDA approved PD-L1 IHC 22C3 pharmDx (Code SK006) as a companion diagnostic test for patients with esophageal or gastroesophageal junction (GEJ) carcinoma who may be candidates for pembrolizumab therapy. The diagnostic assay is designed to detect PD-L1 expression in tumors, aiding clinicians in selecting appropriate patients for immunotherapy treatment.
In April 2025, Researchers showcased emerging therapeutic approaches for esophageal cancer, including innovative immunotherapy combinations, the development of novel biomarkers, and advancements in perioperative treatment strategies. Particular emphasis was placed on broadening the application of PD-1 inhibitors and enhancing treatment responses across both early-stage and metastatic disease settings.
In March 2025, Tislelizumab (TEVIMBRA) received FDA approval in combination with chemotherapy for first-line treatment of unresectable or metastatic esophageal squamous cell carcinoma (ESCC) with PD-L1 expression, marking an important addition to frontline immunotherapy options.
In March 2025, The FDA approved tislelizumab-jsgr (Tevimbra) in combination with platinum-based chemotherapy as a first-line treatment for adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1. This approval further broadens the use of immunotherapy in the frontline management of ESCC.
In January 2025, Nivolumab (OPDIVO) plus chemotherapy continued to demonstrate durable overall survival benefit in patients with advanced gastric, gastroesophageal junction, and esophageal cancers, based on 5-year follow-up results from the Phase III CheckMate-649 trial, reinforcing its role in first-line treatment.
According to DelveInsight’s estimates, the total incident cases of esophageal cancer in the 7MM were approximately 79,000 in 2025.
It has been observed that the incidence of non-squamous cell esophageal cancer is higher (~14,000) as compared to squamous cell esophageal cancer (~8,000) in the United States.
It is observed that esophageal cancer is found to be more incident in males (~17,000) as compared to females (~5,000) in the United States.
Among EU4 and the UK, Germany accounted for the highest number of glioma cases, followed by France, whereas Spain had the lowest number of cases in 2025.
In 2025, among total-stage specific cases, distant esophageal cancer was the most incident followed by regional stage-specific esophageal cancer in Germany.
In the United States, among all the age groups, ≥65 years accounted for the highest number of esophageal cancer cases, i.e., around ~14,000, in 2025, followed by the age-group 45–65 years (~8,000).
Key Esophageal Cancer Companies: Eli Lilly and Company, Bayer, Zymeworks, Jazz Pharmaceuticals, Amgen, Jazz Pharmaceuticals, Zymeworks, BeiGene, AstraZeneca, Symphogen, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Exelixis, Bayer, BeiGene, Lyell Immunopharma, Sichuan Baili Pharmaceutical, AP Biosciences, and others
Key Esophageal Cancer Therapies: Entrectinib (ROZLYTREK), Larotrectinib (VITRAKVI), Tislelizumab (TEVIMBRA), Durvalumab (IMFINZI), Zanidatamab, Lenvatinib (LENVIMA), CYRAMZA (ramucirumab), VITRAKVI (larotrectinib), Zanidatamab, Bemarituzumab, Zanidatamab, Tislelizumab, XB002, LGK974, Abemaciclib, ladiratuzumab vedotin, ATRC-101, SGN-PDL1V, RO7247669, THOR-707, Letetresgene Autoleucel, TNO155, Anlotinib Hydrochloride, Larotinib, SCT-I10A, Serplulimab, CS1001, Camrelizumab, Durvalumab, Sym021, Spartalizumab, Sym022, Sym023, Regorafenib, S095033, INCB099318, RO7121661, KF-0210, SCT200, Ramucirumab, Cabozantinib, JAB-3068, Onivyde, JAB-3312, SGN-B6A, RAPA-201,Ociperlimab, SI B001,Apatinib, and others
The Esophageal Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Esophageal Cancer pipeline products will significantly revolutionize the Esophageal Cancer market dynamics.
Esophageal Cancer Overview
Esophageal Cancer is a type of cancer that develops in the esophagus, the muscular tube that carries food and liquids from the throat to the stomach. The two main types are esophageal squamous cell carcinoma and esophageal adenocarcinoma. Common symptoms include difficulty swallowing, unexplained weight loss, chest discomfort, and persistent indigestion. Major risk factors include tobacco use, alcohol consumption, gastroesophageal reflux disease (GERD), and obesity. Treatment options depend on the cancer stage and may include surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapies.
Get a Free sample for the Esophageal Cancer Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/esophageal-cancer-market
Esophageal Cancer Epidemiology
The Esophageal Cancer epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Esophageal Cancer Epidemiology Segmentation:
The Esophageal Cancer market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:
Total Diagnosed Incident Cases of Esophageal Cancer
Histology-specific Cases of Esophageal Cancer
Gender-specific Cases of Esophageal Cancer
Age-specific Cases of Esophageal Cancer
Mutation-specific Cases of Esophageal Cancer
Total Stage-specific Cases of Esophageal Cancer
Line wise Treated Cases of Esophageal Cancer
Download the report to understand which factors are driving Esophageal Cancer epidemiology trends @ Esophageal Cancer Epidemiology Forecast
Esophageal Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Esophageal Cancer market or expected to get launched during the study period. The analysis covers Esophageal Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Esophageal Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Esophageal Cancer Therapies and Key Companies
Entrectinib (ROZLYTREK): Eli Lilly and Company
Larotrectinib (VITRAKVI): Bayer
Tislelizumab (TEVIMBRA): BeiGene
Durvalumab (IMFINZI): AstraZeneca
Zanidatamab: Zymeworks/Jazz Pharmaceuticals
Lenvatinib (LENVIMA): Merck/Eisai
CYRAMZA (ramucirumab): Eli Lilly and Company
VITRAKVI (larotrectinib): Bayer
Bemarituzumab: Amgen
Zanidatamab: Jazz Pharmaceuticals/Zymeworks
Tislelizumab: BeiGene
Durvalumab: Celgene/MedImmune
Tucatinib: Seagen
M1231: Merck KGaA
APX 005M: Apexigen
Erdafitinib: Janssen Research & Development, LLC
Margetuximab: MacroGenics
AN-0025: Adlai Nortye
Discover more about therapies set to grab major Esophageal Cancer market share @ Esophageal Cancer Treatment Landscape
Esophageal Cancer Market Drivers
Rising incidence of esophageal cancer, particularly adenocarcinoma and squamous cell carcinoma, is increasing demand for effective treatment options.
Growing adoption of immunotherapies, targeted therapies, and precision medicine approaches is improving patient outcomes and expanding the treatment landscape.
Advancements in diagnostic technologies and biomarker testing are enabling earlier detection and personalized treatment strategies.
Increased investment in oncology research and clinical trials is accelerating the development of innovative therapies.
Esophageal Cancer Market Barriers
Late-stage diagnosis in many patients limits treatment effectiveness and contributes to poor survival rates.
High costs associated with advanced therapies, including immunotherapies and targeted treatments, can restrict patient access.
Treatment-related toxicities and adverse events may impact patient adherence and quality of life.
Complex disease biology and tumor heterogeneity pose challenges for drug development and treatment optimization.
Scope of the Esophageal Cancer Market Report
Study Period: 2022-2036
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Esophageal Cancer Companies: Eli Lilly and Company, Bayer, Zymeworks, Jazz Pharmaceuticals, Amgen, AstraZeneca, Symphogen, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Exelixis, Bayer, BeiGene, Lyell Immunopharma, Sichuan Baili Pharmaceutical, AP Biosciences, and others
Esophageal Cancer Therapeutic Assessment: Esophageal Cancer current marketed and Esophageal Cancer emerging therapies
Esophageal Cancer Market Dynamics: Esophageal Cancer market drivers and Esophageal Cancer market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Esophageal Cancer Unmet Needs, KOL’s views, Analyst’s views, Esophageal Cancer Market Access and Reimbursement
To know more about Esophageal Cancer companies working in the treatment market, visit @ Esophageal Cancer Clinical Trials and Therapeutic Assessment
Table of Contents
1. Esophageal Cancer Market Report Introduction
2. Executive Summary for Esophageal Cancer
3. SWOT analysis of Esophageal Cancer
4. Esophageal Cancer Patient Share (%) Overview at a Glance
5. Esophageal Cancer Market Overview at a Glance
6. Esophageal Cancer Disease Background and Overview
7. Esophageal Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Esophageal Cancer
9. Esophageal Cancer Current Treatment and Medical Practices
10. Esophageal Cancer Unmet Needs
11. Esophageal Cancer Emerging Therapies
12. Esophageal Cancer Market Outlook
13. Country-Wise Esophageal Cancer Market Analysis (2022-2036)
14. Esophageal Cancer Market Access and Reimbursement of Therapies
15. Esophageal Cancer Market Drivers
16. Esophageal Cancer Market Barriers
17. Esophageal Cancer Appendix
18. Esophageal Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679 Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
